These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 35887312)

  • 1. Structural Basis of Mutation-Dependent p53 Tetramerization Deficiency.
    Rigoli M; Spagnolli G; Lorengo G; Monti P; Potestio R; Biasini E; Inga A
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.
    Kamada R; Nomura T; Anderson CW; Sakaguchi K
    J Biol Chem; 2011 Jan; 286(1):252-8. PubMed ID: 20978130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 tetramerization: at the center of the dominant-negative effect of mutant p53.
    Gencel-Augusto J; Lozano G
    Genes Dev; 2020 Sep; 34(17-18):1128-1146. PubMed ID: 32873579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
    J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transactivation by partial function P53 family mutants is increased by the presence of G-quadruplexes at a promoter site.
    Vojsovič M; Kratochvilová L; Valková N; Šislerová L; El Rashed Z; Menichini P; Inga A; Monti P; Brázda V
    Biochimie; 2024 Jan; 216():14-23. PubMed ID: 37838351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay.
    Inga A; Monti P; Fronza G; Darden T; Resnick MA
    Oncogene; 2001 Jan; 20(4):501-13. PubMed ID: 11313981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic insight into the destabilization of p53TD tetramer by cancer-related R337H mutation: a molecular dynamics study.
    Yu Y; Dong X; Tang Y; Li L; Wei G
    Phys Chem Chem Phys; 2022 Feb; 24(8):5199-5210. PubMed ID: 35166747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of tetramerization in p53 function.
    Chène P
    Oncogene; 2001 May; 20(21):2611-7. PubMed ID: 11420672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A fluid salt-bridging cluster and the stabilization of p53.
    Lwin TZ; Durant JJ; Bashford D
    J Mol Biol; 2007 Nov; 373(5):1334-47. PubMed ID: 17900613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of an intermonomer salt bridge in the p53 tetramerization domain results in an increased propensity to form amyloid fibrils.
    Galea C; Bowman P; Kriwacki RW
    Protein Sci; 2005 Dec; 14(12):2993-3003. PubMed ID: 16260757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folding of tetrameric p53: oligomerization and tumorigenic mutations induce misfolding and loss of function.
    Lubin DJ; Butler JS; Loh SN
    J Mol Biol; 2010 Jan; 395(4):705-16. PubMed ID: 19913028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C-terminal region of human p53 attenuates buffalo p53 N-terminal-specific transactivation of p21 promoter by modulating tetramerization of the protein.
    Singh M; Mukhopadhyay T
    Mol Cell Biochem; 2018 Jun; 443(1-2):101-110. PubMed ID: 29147811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of p53 protein function through alterations in protein-folding pathways.
    Hupp TR
    Cell Mol Life Sci; 1999 Jan; 55(1):88-95. PubMed ID: 10065154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noncanonical DNA motifs as transactivation targets by wild type and mutant p53.
    Jordan JJ; Menendez D; Inga A; Noureddine M; Bell DA; Resnick MA
    PLoS Genet; 2008 Jun; 4(6):e1000104. PubMed ID: 18714371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An engineered four-stranded coiled coil substitutes for the tetramerization domain of wild-type p53 and alleviates transdominant inhibition by tumor-derived p53 mutants.
    Waterman MJ; Waterman JL; Halazonetis TD
    Cancer Res; 1996 Jan; 56(1):158-63. PubMed ID: 8548757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
    Inga A; Resnick MA
    Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer.
    DiGiammarino EL; Lee AS; Cadwell C; Zhang W; Bothner B; Ribeiro RC; Zambetti G; Kriwacki RW
    Nat Struct Biol; 2002 Jan; 9(1):12-6. PubMed ID: 11753428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversible amyloid formation by the p53 tetramerization domain and a cancer-associated mutant.
    Lee AS; Galea C; DiGiammarino EL; Jun B; Murti G; Ribeiro RC; Zambetti G; Schultz CP; Kriwacki RW
    J Mol Biol; 2003 Mar; 327(3):699-709. PubMed ID: 12634062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence.
    Inga A; Storici F; Darden TA; Resnick MA
    Mol Cell Biol; 2002 Dec; 22(24):8612-25. PubMed ID: 12446780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability and structural recovery of the tetramerization domain of p53-R337H mutant induced by a designed templating ligand.
    Gordo S; Martos V; Santos E; Menéndez M; Bo C; Giralt E; de Mendoza J
    Proc Natl Acad Sci U S A; 2008 Oct; 105(43):16426-31. PubMed ID: 18940924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.